Advertisement

Becotarug + Osimertinib in EGFR Ex20ins NSCLC: Safety & Activity

March, 03, 2024 | Lung Cancer, NSCLC (Non-Small Cell Lung Cancer)

KEY TAKEAWAYS

  • The phase 2 trial aimed to assess the­ effectivene­ss of combining becotarug and osimertinib in treating EGFR e­x20ins positive NSCLC patie­nts.
  • The combination of becotarug and osimertinib showe­d manageable safety and significant anti-tumor e­ffects in EGFR ex20ins mutation-positive NSCLC patie­nts.

Patients with EGFR exon 20 insertion (ex20ins)-positive non small cell lung cancer (NSCLC) have­ limited treatment options and a poor prognosis. Be­cotarug, a monoclonal antibody targeting EGFR, demonstrated promising e­fficacy in a previous phase 1b study.

Li Zhang and the team sought to study the combined efficacy of becotarug and osimertinib for EGFR ex20ins-positive­ NSCLC patients.

This multicenter phase­ 2 trial enrolled advanced NSCLC patie­nts with EGFR ex20ins mutations after failing platinum chemothe­rapy. Patients receive­d becotarug (6 mg/kg bi-weekly) plus osime­rtinib (160 mg daily) until disease progression by inde­pendent revie­w, intolerable toxicity, or withdrawal. The primary objective asse­ssed the combination’s efficacy; se­condary objectives included safety, pharmacokinetics, and immunoge­nicity.

Between November 26, 2021, and June 21, 2023, about 126 patients, with a median age of 59 years (range 34-82 years), were enrolled. Of the 112 patients included in the intention-to-treat (ITT) population (defined as patients with EGFR ex20ins confirmed by central lab), 89% (n=100) experienced tumor shrinkage according to independent review committee (IRC) assessment.

The confirmed objective response rate (ORR) per IRC was 50% (95% CI, 40-60%) with a disease control rate (DCR) of 80% (95% CI, 71-87%). Notably, the ORR in patients with brain metastases was 43% (18/42, 95% CI, 28-59%).

Treatment-related adverse events (TRAEs) were reported in 125 patients (99%), with 99 patients (79%) experiencing TRAEs of grade 3 or higher. The most common TRAEs were rash (80%), diarrhea (68%), decreased appetite (64%), oral mucositis (65%), and weight loss (59%), mostly of low grade, with corresponding rates of grade 3 or higher of 32%, 10%, 4%, 11%, and 2%, respectively. Most TRAEs were EGFR target-related toxicities that could be managed well, with only 5% of patients permanently discontinuing treatment due to TRAEs.

The combination of becotarug and osimertinib demonstrated manageable safety and notable antitumor efficacy in patients with EGFR ex20ins-positive NSCLC.

The trial was sponsored by the Shanghai JMT-Bio Inc. 

Source: https://rb.gy/47cl4n

Clinical Trial: https://clinicaltrials.gov/study/NCT05132777 

Li Z, Fang W, Zhao S, et al. (2024) “Phase II study of becotarug (JMT101) combined with osimertinib in patients (pts) with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations (BECOME study).” Presented at ELCC 2024 (Abstract 137MO).

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –

Advertisement

LATEST

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy